News on Vancocin from BioPortfolio.com http://www.BioPortfolio.com Consolidated Vancocin news from BioPortfolio.com Wed, 10 Feb 2010 12:20:59 GMT en Optimer Pharmaceuticals Announces Positive Results From Second Fidaxomicin Phase 3 Study in Patients With Closhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4026069&HITNO=0&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4026069&THISHREF=http://c.moreover.com/click/here.pl%3fz2530334491%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4026069&HITNO=0&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4026069&THISHREF=http://c.moreover.com/click/here.pl%3fz2530334491%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Optimer Reports Positive Phase III Data for Antibiotic against C. Difficilehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024048&HITNO=1&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024048&THISHREF=http://c.moreover.com/click/here.pl%3fz2528602100%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024048&HITNO=1&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024048&THISHREF=http://c.moreover.com/click/here.pl%3fz2528602100%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: Optimer reports positive results from second Phase III study of antibiotic drughttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4023922&HITNO=2&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4023922&THISHREF=http://c.moreover.com/click/here.pl%3fz2528488693%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4023922&HITNO=2&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4023922&THISHREF=http://c.moreover.com/click/here.pl%3fz2528488693%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Optimer Pharma Rises On Fidaxomicin Study Datahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024531&HITNO=3&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024531&THISHREF=http://c.moreover.com/click/here.pl%3fz2528965192%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024531&HITNO=3&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024531&THISHREF=http://c.moreover.com/click/here.pl%3fz2528965192%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBoston Channel: Optimer Pharma Rises On Fidaxomicin Study Datahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024228&HITNO=4&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024228&THISHREF=http://c.moreover.com/click/here.pl%3fz2528720871%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024228&HITNO=4&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024228&THISHREF=http://c.moreover.com/click/here.pl%3fz2528720871%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBoston Channel: Optimer Pharmaceuticals Announces Positive Results From Second Fidaxomicin Phase 3 Study in Patients With Closhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4019342&HITNO=5&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4019342&THISHREF=http://c.moreover.com/click/here.pl%3fz2526234474%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4019342&HITNO=5&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4019342&THISHREF=http://c.moreover.com/click/here.pl%3fz2526234474%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Top-line results from Optimer Pharmaceuticals' second fidaxomicin Phase 3 trial in CDI patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4019030&HITNO=6&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4019030&THISHREF=http://c.moreover.com/click/here.pl%3fz2526075820%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4019030&HITNO=6&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4019030&THISHREF=http://c.moreover.com/click/here.pl%3fz2526075820%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Optimer Pharma rises on fidaxomicin study datahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4022376&HITNO=7&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4022376&THISHREF=http://c.moreover.com/click/here.pl%3fz2527632858%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4022376&HITNO=7&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4022376&THISHREF=http://c.moreover.com/click/here.pl%3fz2527632858%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: Optimer Pharmaceuticals Product Shows Promise Against Competitorhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4022438&HITNO=8&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4022438&THISHREF=http://c.moreover.com/click/here.pl%3fz2527665594%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4022438&HITNO=8&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4022438&THISHREF=http://c.moreover.com/click/here.pl%3fz2527665594%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSan Diego Business Journal: Optimer's fidaxomicin is as effective as Vancocin in late-stage studyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4022329&HITNO=9&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4022329&THISHREF=http://c.moreover.com/click/here.pl%3fz2527608590%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4022329&HITNO=9&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4022329&THISHREF=http://c.moreover.com/click/here.pl%3fz2527608590%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSmartBrief: Optimer Pharmaceuticals Announces Positive Results From Second Fidaxomicin Phase 3 Study in Patients With Closhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4017203&HITNO=10&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4017203&THISHREF=http://c.moreover.com/click/here.pl%3fz2525037265%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4017203&HITNO=10&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4017203&THISHREF=http://c.moreover.com/click/here.pl%3fz2525037265%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comHouston Chronicle: Optimer Pharmaceuticals Announces Positive Results From Second Fidaxomicin Phase 3 Study in Patients With Closhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4017052&HITNO=11&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4017052&THISHREF=http://c.moreover.com/click/here.pl%3fz2524990890%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4017052&HITNO=11&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4017052&THISHREF=http://c.moreover.com/click/here.pl%3fz2524990890%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR Newswire via Yahoo!: Optimer Pharmaceuticals (OPTR) Announces Positive Phase 3 Resultshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4017589&HITNO=12&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4017589&THISHREF=http://c.moreover.com/click/here.pl%3fz2525215749%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4017589&HITNO=12&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4017589&THISHREF=http://c.moreover.com/click/here.pl%3fz2525215749%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: ViroPharma to Participate in the 28th Annual J.P. Morgan Healthcare Conferencehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3883314&HITNO=13&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3883314&THISHREF=http://c.moreover.com/click/here.pl%3fz2455674046%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3883314&HITNO=13&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3883314&THISHREF=http://c.moreover.com/click/here.pl%3fz2455674046%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMontana's News Station: ViroPharma to Participate in the 28th Annual J.P. Morgan Healthcare Conferencehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3869324&HITNO=14&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3869324&THISHREF=http://c.moreover.com/click/here.pl%3fz2448229692%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3869324&HITNO=14&MSIZE=24&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vancocin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3869324&THISHREF=http://c.moreover.com/click/here.pl%3fz2448229692%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: